1. Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety
- Author
-
Gianfrancesco, Milena A, Schmajuk, Gabriela, Haserodt, Sarah, Trupin, Laura, Izadi, Zara, Jafri, Kashif, Shiboski, Stephen, Sirota, Marina, Adams Dudley, R, and Yazdany, Jinoos
- Subjects
Health Services and Systems ,Biomedical and Clinical Sciences ,Health Sciences ,Clinical Research ,Prevention ,Patient Safety ,Good Health and Well Being ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Antirheumatic Agents ,Autoimmune Diseases ,Female ,Humans ,Hydroxychloroquine ,Longitudinal Studies ,Male ,Middle Aged ,Retrospective Studies ,Risk Factors ,Skin Diseases ,Young Adult ,Guidelines ,Patient safety ,Risk factors ,Clinical Sciences ,Arthritis & Rheumatology ,Clinical sciences ,Allied health and rehabilitation science - Abstract
Evidence suggests that hydroxychloroquine (HCQ) retinal toxicity is more common than previously thought. Adhering to careful weight-based dosing can significantly reduce the risk of this adverse event and is recommended in recent guidelines. We used electronic health record data from a large health system to examine HCQ dosing over a 5-year period and identify risk factors associated with higher dosage of HCQ. We constructed a longitudinal, retrospective cohort of patients with HCQ prescriptions (1681 patients with 3490 prescribing events) between 2012 and 2016. We measured HCQ dosing patterns relative to guidelines (
- Published
- 2017